SEC Filing Summary: Kindly MD, Inc. (NAKA)
Business Context and Reporting Period
This Form 8-K Current Report was filed by Kindly MD, Inc. (not Nakamoto Inc.) on September 15, 2025. The registrant is a Utah corporation with principal executive offices in Salt Lake City, UT. The company is classified as an emerging growth company. Its common stock trades on The Nasdaq Stock Market LLC under the symbol NAKA, and tradeable warrants trade on the OTC Pink Market under the symbol NAKAW.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on regulatory disclosure rather than financial performance data.
Material Changes and Events
- Regulation FD Disclosure: On September 15, 2025, the Company published a letter to shareholders (Exhibit 99.1) announcing the filing of a Form S-3 on September 12, 2025.
- Market Expectations: Management noted in the shareholder letter that the Company expects share price volatility to increase for a period of time following the Form S-3 filing.
Guidance, Outlook, and Risks
- Management Commentary: Despite the anticipated volatility, management emphasized its commitment to the Company's long-term vision.
- Risks: The primary risk highlighted is increased share price volatility associated with the recent Form S-3 filing.
- Unusual Items: None reported beyond the standard disclosure of the Form S-3 filing and associated market expectations.
Investor Verification Checklist
- Verify the details of the Form S-3 filed on September 12, 2025, to understand the specific securities being registered.
- Review the full text of the Letter to Shareholders (Exhibit 99.1) for additional context on the Form S-3 purpose.
- Monitor trading activity for NAKA and NAKAW given the explicit warning of increased volatility.
- Confirm the company's status as an emerging growth company and any implications for financial reporting standards.